Olympus launches second VC fund with $150m commitment

Olympus Corporation has committed $150m to a caller task superior (VC) fund, aiming to deploy the superior to promising medtech startups successful the gastrointestinal (GI), urology, and respiratory sectors.

Olympus Innovation Ventures’ (OIV) Fund II is being established by OIV, a wholly owned subsidiary of Olympus Corporation of the Americas. The money aims to make a pipeline of M&A opportunities, partnerships, and invaluable marketplace insights.

OIV Fund II is positioned arsenic a ‘stage-agnostic’ VC money that aims to prioritise aboriginal to growth-stage companies globally with therapeutic solutions for targeted aesculapian specialities. Olympus highlighted that OIV volition besides proceed assisting its existing portfolio companies that were added via its archetypal VC fund, which was launched successful 2021.

The inaugural fund, called OIV Fund I, had a superior allocation of $50m and has invested successful 9 medtech startups, including US-based molecular imaging cause developer On Target Laboratories and Spain-based non-invasive colorectal crab trial developer Universal Diagnostics.

Olympus's main strategy serviceman and OIV Investment Committee seat Gabriela Kaynor commented: “With an further committedness to firm task capital, we volition proceed to marque investments successful startup teams who are gathering unsocial solutions successful endoscopy-enabled care.”

Corporate VC specializer Cerity Partners Ventures volition proceed to assistance negociate OIV’s 2nd fund, having partnered with the VC limb since its archetypal fund’s launch.

Cerity spouse Kindra Tatarsky said: "The Cerity Partners Ventures squad is excited to proceed moving with Olympus, leveraging our corporate method strengths, manufacture relationships, and taxable substance expertise to money and enactment starring entrepreneurs.

“This money volition physique connected Olympus Innovation Ventures’ ngo to beryllium the spouse of prime for innovators, creating a competitory vantage for their startups.”

In confluence with its caller absorption connected GI startup concern via OIV, Olympus is aiming to carve retired its ain presumption successful the market. In July, Olympus founded a caller endoluminal robotics startup named Swan EndoSurgical Robotics alongside backstage equity steadfast Revival Healthcare Capital.

Swan volition absorption connected processing an endoluminal surgical robotics level for treating lesions oregon tumours successful the GI tract, with the institution stating that Swan aims to make a strategy that improves minimally invasive options for treatments specified arsenic crab resection by overcoming the “ergonomic limitations” of manual endoscopy.

"Olympus launches 2nd VC money with $150m commitment" was primitively created and published by Medical Device Network, a GlobalData owned brand.